Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Matritech

This article was originally published in The Gray Sheet

Executive Summary

Submits premarket approval application to FDA on Nov. 9 for its NMP22 test kit for detecting and monitoring bladder cancer. The kit is based on the company's nuclear matrix protein technology. Matritech plans to sell the test for $20-$30 each; "four or five tests per year could be required on patients needing frequent monitoring," the company notes. Other NMP assays in Matritech's pipeline include tests for breast, cervical, colorectal and prostate cancers
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT003125

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel